LIMBIX, an invested company of BIXINK, launches SparkRx under the U.S FDA Emergency Use Authorization : BIXINK

Notifications

LIMBIX, an invested company of BIXINK, launches SparkRx under the U.S FDA Emergency Use Authorization

7 Oct 2021

Views 687

https://view.asiae.co.kr/article/2021100710284682831

0

BIXINK obtains market authorization of Nerlynx in Korea for early breast cancer Bixink, as a first Korean company, to initiate study for its digital therapeutics device “OC FREE” in the U.S. soon

List